News
11-19-2010, 01:40 AM
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced results from a Phase 1b clinical trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, in patients with advanced gastrointestinal (GI) cancers.
More... (http://www.news-medical.net/news/20101119/AVEO-announces-results-from-tivozanib-Phase-1b-clinical-trial-for-advanced-gastrointestinal-cancers.aspx)
More... (http://www.news-medical.net/news/20101119/AVEO-announces-results-from-tivozanib-Phase-1b-clinical-trial-for-advanced-gastrointestinal-cancers.aspx)